Glaxo to begin clinical trial of Ebola vaccine

|By:, SA News Editor

GlaxoSmithKline (NYSE:GSK) is set to begin a clinical trial of an experimental vaccine against Ebola, which is being co-developed with U.S. scientists.

The experimental vaccine has already produced promising results in animal studies, and with an approval from the FDA, it will enter initial Phase I testing in humans.

Still, the new vaccine will not be ready for widespread deployment before 2015 - even assuming it works as well as hoped.